-
Govt takes control of Turkey's most-watched news channel
-
Bournemouth boss Rose urges Cherries to bounce back from Chelsea 'slap'
-
FIFA to offer members $6.35-billion development fund windfall
-
Top seed Sabalenka falls at first hurdle in Wuhan
-
US consumer inflation hotter than expected as midterms loom
-
FX Junction Brings Copy Trading to Everyone, While Their Money Never Leaves With Their Broker
-
INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro
-
Brighton defender Struijk's red card overturned
-
Hot US inflation data dents Wall Street stocks
-
Saudi league postpones three matches after Houthi attacks
-
India sends 'cockroach' leaders to jail after protest
-
US consumer inflation up more than expected as midterms loom
-
'Sinners' director Ryan Coogler to reboot 'X-Files' for Disney
-
Canadian publisher supports novelist Orelien after AI denial
-
Lufthansa wins contest for TAP Air Portugal stake
-
Medvedev sees off Tsitsipas to reach Shanghai Masters quarters
-
AI worms, 'major' incident fears spur safety calls at industry summit
-
Louvre boss warns of closure risk without major renovations
-
Fuel shortage triggers queues on Indonesia's Bali island
-
Lawes and Genge urge England to end ban on overseas-based players
-
Evolution Metals & Technologies Corp. Reaffirms $400 Million to $460 Million FY2027 Revenue Guidance, Unveils Eight Sintered Magnet Grades Covering an Estimated 75% of Global NdFeB Revenue, and Moves to Answer U.S. Army Call for Rare Earth Magnets
-
Metrika Selected by OCC to Support Stablecoin Supervisory Framework Under the GENIUS Act
-
Trial defence says Russia used Nord Stream pipelines as 'weapon'
-
Kenya hosting 2029 World Championships will help doping fight, says Coe
-
Israeli settlers set fire to mosque in occupied West Bank
-
UK prosecutor tells jury Russell Brand a 'sexual predator'
-
Macron says French student protesters 'exploited' by political forces: spokeswoman
-
Fulham manager Arbeloa fined £25,000 after Man Utd outburst
-
Stocks diverge ahead of key US inflation data
-
Nepal flood triggered by rock and ice avalanche: report
-
Japan summons Russian ambassador to protest journalist's arrest
-
'Distressed' family of UK man killed by tiger urge end to online posts
-
Workers to strike at world's largest copper mine in Chile
-
Regulator expects Man City appeal to be heard by January
-
Ukraine accuses US of helping Russia as missiles hit Kyiv
-
Rising Spanish tennis star handed code violation for swearing at ballboy
-
Drone hits data centre of Russia's largest bank
-
Last of the French musketeers Monfils officially retired from tennis
-
Bivial AG Brings Its Complete Dashboard to Mobile
-
Ukraine ex-military officer stands trial over Nord Stream sabotage
-
Mont Blanc nearly two metres taller than in 2023: French surveyors
-
British and Irish Lions to play first women's match against France
-
Pope recovering after lung cancer operation that rattles Church
-
Fuel shortage triggers queues on resort island Bali
-
Indonesia haze spikes Singapore pollution, shuts East Timor schools
-
Sao Tome's niche vanilla finds far-away fans
-
Higher borrowing costs an 'alarm signal' for France: finance minister
-
China-North Korea bridge to open Thursday, 12 years late
-
Zelensky accuses Putin of disrespecting Trump after latest attacks
-
Asian stocks mostly down as tech firms struggle to claw back losses
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.
Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."
"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."
AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.
[email protected]
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
Th.Gonzalez--AT